Welcome to our dedicated page for Viking Therapeutics SEC filings (Ticker: VKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viking Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, and clinical-development disclosures for VK2735, including subcutaneous and oral obesity programs, trial results, and related regulatory communications.
The company's proxy materials disclose board and shareholder-voting matters, executive compensation, equity awards, and pay-versus-performance information. Viking's SEC record also covers Regulation FD communications, clinical-development updates, cash resources, and governance matters tied to a development-stage biotechnology issuer.
Viking Therapeutics (VKTX) filed its Q3 2025 report, showing higher R&D as programs advanced and a wider loss. For the quarter, net loss was $90.8 million, or $0.81 per share, driven by research and development expense of $89.9 million and general and administrative expense of $8.6 million. There was no revenue.
Liquidity remained strong with cash and cash equivalents of $100.4 million and short‑term investments of $614.2 million as of September 30, 2025. For the nine months, the company used $193.4 million in operating cash. Stockholders’ equity was $713.0 million.
Capital markets tools are in place: an S‑3 shelf effective July 2023, ATM capacity remaining up to $151.9 million, and a $250.0 million repurchase program authorized in February 2025 (no repurchases in Q3). The March 2024 offering provided $597.1 million net proceeds. Shares outstanding were 113,036,344 as of October 15, 2025.
Operationally, Viking entered multi‑year manufacturing agreements for VK2735 with prepayments from 2025 to 2028 credited against future orders. A subsequent lease amendment expands headquarters space, with $63,000 monthly base rent starting on the later of substantial completion or April 1, 2026.
Viking Therapeutics (VKTX) furnished an 8-K announcing it issued a press release reporting financial results for the third quarter ended September 30, 2025 and providing a corporate update. The press release is included as Exhibit 99.1. The company notes that the information under Item 2.02 is furnished, not filed, under the Exchange Act.
Viking Therapeutics, Inc. filed a current report to highlight that, on August 19, 2025, it issued a press release announcing top-line results from its Phase 2 clinical trial of the oral tablet formulation of VK2735. The company furnished this press release as Exhibit 99.1 and clarified that the information provided under the Regulation FD disclosure section is being furnished rather than filed for liability purposes under securities laws.